There is currently no text in this page. You can search for this page title in other pages, or search the related logs, but you do not have permission to create this page.
Category:CPC A61K47/6807
Pages in category "CPC A61K47/6807"
The following 24 pages are in this category, out of 24 total.
2
- 20250152726. Nucleic Acid-polypep (Avidity Biosciences, .)
- 20250152726. Nucleic Acid-polypep (Avidity Biosciences, Inc.)
- 20250152727. Muscle Targeting Compl (Dyne Therapeutics, .)
- 20250152727. Muscle Targeting Compl (Dyne Therapeutics, Inc.)
- 20250170259. Compositions Methods D (Yale University)
- 20250170260. Nucleic Acid-polypep (Avidity Biosciences, .)
- 20250170261. Muscle Targeting Compl (Dyne Therapeutics, .)
- 20250177548. Fusogenic Peptide Compositi (CLEMSON UNIVERSITY)
- 20250177549. Muscle Targeting Compl (Dyne Therapeutics, .)
- 20250186605. Muscle Targeting Compl (Dyne Therapeutics, .)
- 20250195676. Compositions Met (Avidity Biosciences, .)
- 20250205352. Compositions Methods (Eli Lilly and)
- 20250213714. Anti-sez6 Antibody Drug (ABBVIE STEMCENTRX LLC)
- 20250228957. Bifunctional Degrad (Biohaven Therapeutics .)
A
- Arizona Board of Regents on behalf of Arizona State University Patent Application Trends in 2025
- Arizona Board of Regents on Behalf of Arizona State University Patent Application Trends in 2025
- ASTELLAS PHARMA INC. Patent Application Trends in 2024
- Avidity Biosciences, Inc. (20250108120). COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
- Avidity Biosciences, Inc. (20250121085). ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 45 SKIPPING